Japanese research lab to use an IBM supercomputer for protein research

IBM announced today that AIST, a leading Japanese research laboratory, will use an IBM BlueGene/L supercomputer to advance their research in proteins, potentially accelerating breakthroughs in drug design. The BlueGene/L supercomputer has been ranked as the fourth largest supercomputer in the world.

The Computational Biology Research Center (CBRC) of The National Institute of Advanced Industrial Science and Technology (AIST) will use the extreme computational power of BlueGene/L to better predict 3-D protein structures, key to understanding how drugs interact with diseases. IBM Research and AIST are also exploring possible areas for joint research using application software IBM has specifically designed to tackle protein simulations on BlueGene/L.

Expected to be installed in February 2005, the BlueGene/L system will consist of four racks, with a peak processing speed of 22.8 trillion calculations per second, or 22.8 teraflops. The BlueGene/L supercomputer will be 24 times more powerful and use a fraction of the floor space compared to the CBRC's current computer systems. BlueGene/L consumes at most 1/10th the power per computation and 1/16th the floor space of systems of comparable compute power found on the Top 500 list of most powerful supercomputers.

"One of our biggest research challenges is to apply data obtained from genome decoding to protein engineering and drug design. The scale of simulation this requires cannot be done without the help of supercomputers," said Dr. Yutaka Akiyama, director, Computational Biology Research Center, AIST. "IBM's BlueGene/L supercomputer provides us with a massive supercomputing resource that will dramatically accelerate our work."

The AIST scientists are developing parallel and distributed computing techniques for solving large-scale data processing and searching problems in bioinformatics. The team is also creating high performance computer applications for molecular simulation, mass spectrometry analysis, and cell simulation.

"From the beginning, IBM's commitment to developing the most powerful and flexible supercomputers in the world has included a focus on tackling the biggest challenges in life sciences," said William Pulleyblank, director of exploratory server systems, IBM Research. "AIST's dedication to advanced life sciences research is the perfect opportunity to combine the world's most advanced supercomputer with a leading research institution to attack a major scientific challenge."

If it were installed today, this supercomputer would rank third in the world on the list of the Top 500 supercomputers announced in June 2004. Two early prototype BlueGene/L supercomputers were ranked as the fourth and eighth largest supercomputers in the world in June (http://www.top500.org/list/2004/06/). These systems exploit the advanced processors based on IBM's Power Architecture. Earlier this year, IBM announced its Power Everywhere initiative, designed to make this same IBM Power Architecture more widely available for everything from consumer electronics to supercomputers.

Blue Gene is an IBM supercomputing project which is creating a new family of supercomputers optimized for bandwidth, scalability and the ability to handle large amounts of data while consuming a fraction of the power and floor space required by today's fastest systems. The project originated in 1999 in IBM's Research Division and is expected to be used worldwide by government and university researchers as well as businesses to tackle the most advanced challenges in several very different fields, including genomic research, automotive design, finance, weather forecasting and fluid dynamics. The Argonne National Laboratory in the US and ASTRON, a leading Dutch astronomical organization, will also be installing BlueGene/L supercomputers in 2005 to tackle unique scientific challenges.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study